NASDAQ:EOLS Evolus (EOLS) Stock Price, News & Analysis → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free EOLS Stock Alerts $10.88 -0.45 (-3.97%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$10.87▼$11.3850-Day Range$10.88▼$13.7052-Week Range$7.07▼$15.43Volume676,787 shsAverage Volume604,756 shsMarket Capitalization$681.09 millionP/E RatioN/ADividend YieldN/APrice Target$21.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Evolus alerts: Email Address Evolus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside99.1% Upside$21.67 Price TargetShort InterestBearish8.26% of Float Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment1.37Based on 4 Articles This WeekInsider TradingSelling Shares$2.93 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.61) to $0.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.86 out of 5 starsMedical Sector236th out of 913 stocksPharmaceutical Preparations Industry102nd out of 429 stocks 3.5 Analyst's Opinion Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvolus has only been the subject of 2 research reports in the past 90 days.Read more about Evolus' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.26% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Evolus has recently decreased by 4.09%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEvolus has received a 40.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private dermatologist's appointments", "Private internist's appointments", and "Botulinum toxin" products. See details.Environmental SustainabilityThe Environmental Impact score for Evolus is -1.27. Previous Next 3.0 News and Social Media Coverage News SentimentEvolus has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Evolus this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,934,339.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Evolus is held by insiders.Percentage Held by Institutions90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Evolus' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.61) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -10.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -10.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Evolus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> About Evolus Stock (NASDAQ:EOLS)Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Read More EOLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EOLS Stock News HeadlinesJune 7, 2024 | insidertrades.comEvolus, Inc. (NASDAQ:EOLS) Insider David Moatazedi Sells 155,278 SharesJune 6, 2024 | insidertrades.comEvolus, Inc. (NASDAQ:EOLS) Director Vikram Malik Sells 7,500 SharesJune 12, 2024 | businesswire.comEvolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in SpainJune 9, 2024 | americanbankingnews.comEvolus (NASDAQ:EOLS) Trading Down 6% on Insider SellingJune 7, 2024 | businesswire.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 24, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Evolus (EOLS)May 22, 2024 | markets.businessinsider.comStrong Buy Rating for Evolus Backed by Growth Potential and Market Penetration ProspectsMay 22, 2024 | seekingalpha.comEvolus: Chiseling Away At The Aesthetic MarketMay 20, 2024 | stockhouse.comEvolus Announces Positive Data from Pivotal Trial for First Two Evolysse(TM) Dermal Filler Products at 2024 SCALE MeetingMay 20, 2024 | businesswire.comEvolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE MeetingMay 16, 2024 | finance.yahoo.comDirector Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS)May 16, 2024 | finance.yahoo.comDirector David Gill Sells 10,361 Shares of Evolus Inc (EOLS)May 15, 2024 | finance.yahoo.comEvolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO SummitMay 15, 2024 | businesswire.comEvolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO SummitMay 13, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Evolus (EOLS)May 10, 2024 | finance.yahoo.comEvolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the YearMay 10, 2024 | businesswire.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | businesswire.comEvolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the YearMay 10, 2024 | markets.businessinsider.comEvolus’s Strong Q1 Performance and Solid Growth Trajectory Justify Buy RatingMay 10, 2024 | markets.businessinsider.comEvolus Outperforms Expectations with Strong Q1 Sales and Promising Growth TrajectoryMay 9, 2024 | finance.yahoo.comEvolus First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 8, 2024 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comEvolus Inc (EOLS) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth and Strategic ...May 7, 2024 | investorplace.comEOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comEvolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant GrowthSee More Headlines Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/17/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EOLS CUSIPN/A CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees279Year FoundedN/APrice Target and Rating Average Stock Price Target$21.67 High Stock Price Target$27.00 Low Stock Price Target$16.00 Potential Upside/Downside+95.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,690,000.00 Net Margins-27.31% Pretax Margin-27.22% Return on EquityN/A Return on Assets-28.50% Debt Debt-to-Equity Ratio6.54 Current Ratio3.21 Quick Ratio2.96 Sales & Book Value Annual Sales$202.09 million Price / Sales3.43 Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-30.72Miscellaneous Outstanding Shares62,600,000Free Float58,781,000Market Cap$692.36 million OptionableOptionable Beta1.32 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. David Moatazedi (Age 46)President, CEO & Director Comp: $1.75MMs. Sandra Beaver (Age 46)Chief Financial Officer Comp: $740.15kDr. Rui Avelar C.CFP (Age 62)Dip.SportMed, M.D., Chief Medical Officer and Head of Research & Development Comp: $823.19kMr. Nareg SagherianHead of Global Investor Relations & Corporate CommunicationsMr. Jeffrey J. PlumerGeneral CounselMr. Kurt KnabVice President of SalesMs. Tomoko Yamagishi-DresslerChief Marketing OfficerMs. Jessica NovakSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsAdamas PharmaceuticalsNASDAQ:ADMSXenon PharmaceuticalsNASDAQ:XENEPTC TherapeuticsNASDAQ:PTCTMorphoSysNASDAQ:MORMoonLake ImmunotherapeuticsNASDAQ:MLTXView All CompetitorsInsiders & InstitutionsDavid MoatazediSold 155,278 sharesTotal: $2.01 M ($12.92/share)Vikram MalikSold 7,500 sharesTotal: $97,200.00 ($12.96/share)Zimmer Partners LPBought 300,000 shares on 5/17/2024Ownership: 0.479%FourWorld Capital Management LLCSold 50,000 shares on 5/16/2024Ownership: 0.245%California State Teachers Retirement SystemBought 739 shares on 5/16/2024Ownership: 0.077%View All Insider TransactionsView All Institutional Transactions EOLS Stock Analysis - Frequently Asked Questions Should I buy or sell Evolus stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EOLS shares. View EOLS analyst ratings or view top-rated stocks. What is Evolus' stock price target for 2024? 3 brokerages have issued twelve-month price objectives for Evolus' shares. Their EOLS share price targets range from $16.00 to $27.00. On average, they predict the company's stock price to reach $21.67 in the next year. This suggests a possible upside of 99.1% from the stock's current price. View analysts price targets for EOLS or view top-rated stocks among Wall Street analysts. How have EOLS shares performed in 2024? Evolus' stock was trading at $10.53 at the beginning of the year. Since then, EOLS shares have increased by 3.3% and is now trading at $10.88. View the best growth stocks for 2024 here. When is Evolus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our EOLS earnings forecast. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) posted its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.05. The business had revenue of $59.33 million for the quarter, compared to analyst estimates of $58.78 million. What ETFs hold Evolus' stock? ETFs with the largest weight of Evolus (NASDAQ:EOLS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has Evolus issued on next quarter's earnings? Evolus updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $262.8 million. What is David Moatazedi's approval rating as Evolus' CEO? 1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Organigram (OGI) and Bionano Genomics (BNGO). When did Evolus IPO? Evolus (EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. Who are Evolus' major shareholders? Evolus' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.64%), Rice Hall James & Associates LLC (1.52%), Lord Abbett & CO. LLC (1.33%), BNP Paribas Financial Markets (0.65%), Zimmer Partners LP (0.48%) and Essex Investment Management Co. LLC (0.41%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Karah Herdman Parschauer, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar, Sandra Beaver and Vikram Malik. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EOLS) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.